Specify a stock or a cryptocurrency in the search bar to get a summary
Dyadic International Inc
DYAIDyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design,Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida. Address: 140 Intracoastal Pointe Drive, Jupiter, FL, United States, 33477-5094
Analytics
WallStreet Target Price
7.5 USDP/E ratio
–Dividend Yield
0.84 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures DYAI
Dividend Analytics DYAI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DYAI
Stock Valuation DYAI
Financials DYAI
Results | 2019 | Dynamics |